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 Mycobacterium abscessus is an emerging human pathogen which is difficult to 
treat and results in increased mortality. Moreover, the cause of increasing case rates 
and also the pathogenesis of M. abscessus are poorly understood. M. abscessus 
belongs to the family of nontuberculous mycobacteria (NTM) classified as members of 
the rapidly growing mycobacteria (RGM). These environmental pathogens are 
ubiquitous and found in shower heads, tap water, natural water sources, and soil. 
Humans contract pulmonary or disseminated infections with M. abscessus by breathing 
in the aerosolized bacteria or ingesting contaminated water. Immunocompromised 
individuals such as HIV or AIDS patients, are more susceptible to infection with M. 
abscessus as are those with cystic fibrosis, bronchiectasis, and individuals on tumor 
necrosis factor α (TNFα) inhibitors. Strangely, an increasing population of patients 
becoming infected with M. abscessus are immunocompetent, tall, slender, Caucasian, 
non-smoking women. 
 To expand our understanding of M. abscessus pathogenesis we developed 
mouse models that maintain high levels of bacterial infection to study immune 
responses induced by clinical strains of M. abscessus. Our results support the 
hypothesis that this bacteria can only persist in our animal models that possess a 
deficiency in macrophages and T cell function. Clustered bacterial strains obtained from 
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Cystic Fibrosis patients are more virulent than unclustered bacterial strains obtained 
from Cystic Fibrosis patients. Additionally, counts of viable mycobacterial colony forming 
units and histological analysis in (Severe Combined Immunodeficiency) SCID mice on a 
beige background infected with clustered versus unclustered M. abscessus strains 
which were isolated from Cystic Fibrosis patients also supported the increased virulence 
exhibited by the clustered strains. Lastly, we show that major human M. abscessus 
outbreak strains, when infecting IL-3, GM-CSF deficient mice on an IL-2, Rag2 deficient 
background (GM/Rag-dblKO mice), result in increased bacterial replication and organ 
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1.1 Historical and Current Relevance of M. abscessus 
M. abscessus is a ubiquitous, rapidly growing, acid fast bacillus (AFB) which can be 
found in soil, tap water, and shower heads [1, 2]. Ernest Runyon developed a system of 
identifying nontuberculous mycobacteria in the 1950s [3]. This included classification 
based on pigmentation and growth rates [3, 4]. This system of identification is discussed 
further in the next section. There are three distinct subspecies of M. abscessus 
including M. abscessus sbsp. massiliense, sbsp. abscessus, and sbsp. bolletii, which 
are discussed further below [5].  M. abscessus is an emerging human pathogen whose 
impact has grown considerably in the past decade [6, 7]. Mycobacteria have a unique 
cell wall made up of mycolic acid, peptidoglycan, and arabinogalactan, which likely 
contributes to their drug resistance and virulence [8, 9]. Clinical strains of M. abscessus 
can have smooth, rough, or mixed morphology [10, 11]. The association of the bacterial 
morphology and its implication on disease outcome are poorly understood. However, 
generally a rough morphology predicts a worse clinical outcome due to the cords which 
interfere with macrophage phagocytosis [10, 11, 12]. The smooth morphology 
associated with glycopeptidolipid (GPL) production confers the ability of these 
organisms to form biofilms [13, 14]. Biofilm formation allows smooth variants of M. 
abscessus to colonize the environment [13, 14]. 
Pulmonary or disseminated disease is caused by inhalation of aerosolized M. 
abscessus or even by person to person transmission [15, 16]. Additionally, cutaneous 
infections can result from exposure to M. abscessus by non-sterile tattooing practices, 
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unclean needles used for acupuncture treatments, or use of contaminated surgical 
equipment, often for cosmetic surgery [17, 18, 19]. It has long been thought that only 
immunocompromised humans were susceptible to infection with M. abscessus. 
However, recent evidence points to the possibility that immunocompetent individuals 
are becoming infected with M. abscessus as well [15, 20]. Even so, 
immunocompromised individuals such as HIV or AIDS patients and lung transplant 
patients are more susceptible to infection with M. abscessus than are members of the 
general population [15, 21]. Cystic fibrosis patients are also at a higher risk for 
contracting M. abscessus infection [14, 22].  Structural abnormalities of the lungs, such 
as bronchiectasis, contribute to host susceptibility as well [16, 21]. Additionally, 
immunocompetent, post-menopausal Caucasian, non-smoking, tall, slender females 
tend to be at higher risk for M. abscessus infection [23]. This may be caused by the 
elongation of the chest cavity in tall, slender women [23]. Further, it has been suggested 
that because slender patients have less leptin and more adiponectin, they are more 
susceptible to infection with M. abscessus [14]. This hypothesis is supported by a study 
in which leptin deficient mice were found to be more susceptible to M. abscessus 
infection [14]. Moreover, lower levels of leptin lead to decreased expression of T helper 
1 (Th1) cells, which kill intracellular pathogens such as M. abscessus [14]. Increased 
levels of adiponectin upregulate the expression of interleukin 10 (IL-10) and the 
expression of IL-1R antagonist, which prevents the expression of TNFα [14]. Since 
moderate expression of TNFα is protective against mycobacterial infection, this leads to 
more severe disseminated disease [14]. Additionally, it is thought that perhaps women 
cough less effectively than men for social reasons, otherwise known as “Lady 
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Windermere syndrome” [3, 14]. This may create difficulty in clearing the bacteria from 
the lungs. A lack of estrogen in post-menopausal women may be responsible for the 
increased susceptibility of this particular demographic [14]. The binding of estrogen to 
estrogen receptors on macrophages induces phagocytosis [14]. Thus, without estrogen, 
macrophages may be less likely to phagocytose M. abscessus. The growing list of 
effects of M. abscessus upon public health points to the great need for further study of 
pathogenesis and effective drug therapies against this pathogen. 
As stated previously, three different subspecies of M. abscessus including M. 
abscessus sbsp. abscessus, sbsp. massiliense, and sbsp. bolletii have been isolated 
from infected patients [5]. The traditional drug regimen for treatment of M. abscessus 
infection includes a macrolide such as clarithromycin or azithromycin, amikacin, which is 
an aminoglycoside, and either a fluoroquinolone such as levofloxacin or ciprofloxacin, or 
else a cephalosporin such as cefoxitin [26, 27]. Macrolides and aminoglycosides bind to 
the 50S and 30S ribosomal subunits, respectively, to inhibit protein synthesis by M. 
abscessus [28]. Macrolides also function by binding to the 23S ribosomal RNA (rRNA) 
to inhibit protein synthesis [29]. Aminoglycoside resistance is conferred upon M. 
abscessus strains by a p55 efflux pump [3]. Fluoroquinolones interfere with nucleic acid 
synthesis [28]. Cephalosporins are β-lactams, which interfere with cell wall synthesis 
[28, 30]. Many isolates of M. abscessus sbsp. abscessus, as well as some isolates of 
M. abscessus sbsp. massiliense, have demonstrated expression of erythromycin 
ribosome methyltransferase (41) genes (erm(41) genes) [24]. These erm(41) genes 
confer inducible macrolide resistance in these pathogens by methylation of the 23S 
rRNA [3, 24, 25]. Because of the inducible macrolide resistance expressed by many 
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clinical isolates of M. abscessus, this pathogen is incredibly difficult to treat [31]. Often 
patients are on this course of antibiotics for months at a time [32]. This may also be due 
to the fact that M. abscessus is an intracellular pathogen, which is able to survive within 
macrophages [33, 34]. This protects the bacteria from host defenses as well as 
exposure to drug compounds, and contributes to the chronic nature of infection [34]. 
Many individuals develop liver toxicity from prolonged exposure to antibiotics [26]. It is 
common for patients to have pieces of their lungs resected in order to eradicate the M. 
abscessus [35, 36, 37]. Even after successful treatment, many patients will experience 
relapse of the disease [35]. In one case, a lung transplant patient was diagnosed with 
subsequent pulmonary M. abscessus infection, and was treated successfully. However, 
one month later this patient developed deep gluteal abscesses caused by relapse of the 
M. abscessus infection, and eventually succumbed to bronchiolitis obliterans [35]. Thus, 
it is important to find more efficacious drug treatment regimens to prevent relapse. We 
will expand further on the drug resistance of M. abscessus in Section 1.3. 
There are known differences between the human immune profile, and the murine 
immune response [38]. For example, humans produce interleukin-32 (IL-32), a pro-
inflammatory cytokine which is not expressed in mice [39, 40]. The immune response to 
pulmonary or disseminated M. abscessus infection in humans has been well 
characterized [23]. Additionally, there is a growing body of knowledge regarding the 
pathogenesis of M. abscessus in humans. For example, we have recently learned that 
unlike slow-growing mycobacteria, M. abscessus is less likely to survive over time 
inside of macrophages, and more commonly destroys macrophages leading to the 
damaging release of reactive oxygen species [20]. The persistence of M. abscessus 
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within phagosomes of human macrophages may depend on whether the strain has 
rough or smooth morphology [10]. Upon infection of alveolar cells with M. abscessus, an 
adaptor protein found on toll-like receptors (TLRs) called MyD88 (myeloid differentiation 
primary response gene 88) activates the NF-κB (nuclear factor kappa-light-chain-
enhancer of activated B cells) pathway, which produces cytokines that mediate 
inflammation [6]. 
We hypothesize that GM/Rag-dblKO mice (Table 1) and SCID mice on a beige 
background will allow us to understand the host immune response to infection with NTM 
and pathogenesis of M. abscessus. We suspect that these mice will demonstrate high 
bacterial loads into chronic infection, much like human patients, and unlike most other 
mouse strains which do not obtain high bacterial burdens [41]. GM/Rag-dblKO mice 
express human colony stimulating factor 2 (Csf2) and human interleukin-3 (IL-3) [42]. 
Thus, they promote the development of human alveolar macrophages, and demonstrate 
pulmonary disease processes that are commonly observed in human patients [41, 42]. 
The development of human alveolar macrophages within the GM/Rag-dblKO mice 
allowed Willinger, et al. to extract the macrophages from sickened mice, and use them 
for in vitro studies [42]. For our purposes, the human alveolar macrophages are non-
functional in vivo. Thus, the knock-in of the human Csf2 is effectively equivalent to a 
knockout of Csf2 in our study. The GM/Rag-dblKO mice are on a recombination 
activating gene 2 knockout (Rag2-/-) interleukin-2 (IL-2) -/- background [42]. Thus, the 
GM/Rag-dblKO mice produce neither functional T cells nor functional B cells [42]. In 
order to understand the pathogenesis of M. abscessus, we carried out experiments 
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comparing the survival rates of GM/Rag-dblKO mice to those of SCID mice on a beige 
background upon infection with M. abscessus.  
The GM/Rag-dblKO mice were developed by Flavell, Willinger, and their associates 
as described by Willinger, et al [42]. IL-3 stimulates the proliferation of myeloid cells, 
specifically, pro-inflammatory granulocytes and monocytes [43]. Csf2 promotes the 
proliferation of pro-inflammatory granulocytes and monocytes, which differentiate into 
macrophages and dendritic cells [42]. Together, IL-3 and Csf2 promote the 
development of alveolar macrophages [42]. Rag2 is responsible for the production of 
lymphocytes including T cells and B cells [44]. It is important to note that the absence of 
Rag2 does not inhibit the production of natural killer (NK) cells [45]. IL2 regulates 
inflammatory response by promoting the expansion of regulatory T cells which suppress 
inflammation [46]. Thus, these mice have non-functional granulocytes, macrophages, T 
cells, and B cells. Clearly, these mice have an extremely depleted immune system. 
While the immune response to influenza viral infection in GM/Rag-dblKO mice has 
been characterized, the immune response to M. abscessus infection in GM/Rag-dblKO 
mice has not yet been characterized in the literature [42]. The GM/Rag-dblKO mice lack 
functional lymphocytes because they are on a Rag2 -/- background [44]. Furthermore, it 
has been observed that cystic fibrosis patients infected with M. abscessus have a 
higher level of CD40L+ (Cluster of Differentiation marker 40 Ligand positive) IL2- 
(Interleukin 2 negative) T cells [47]. This indicates that IL-2 contributes to protective 
immunity against M. abscessus infection [45]. Thus, the GM/Rag-dblKO mice will be 
more susceptible to infection with M. abscessus because they do not produce IL-2. 
Therefore, these mice will demonstrate high bacterial loads into chronic infection, much 
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like human patients, and unlike most other mouse strains which do not obtain high 
bacterial burdens [41]. Although it has been proposed by De Groote, et al. that the 
GMCSF-/- mouse is a good model for infection and preclinical testing of 
antimycobacterial compounds, this mouse does not attain high bacterial burdens in the 
spleen over time [48]. This implies that the mouse is not experiencing disseminated 
infection, unlike humans who often do develop disseminated disease over the course of 
chronic infection [35]. We will use flow cytometry to determine whether GM/Rag-dblKO 
mice are immunologically similar to humans upon infection with M. abscessus and to 
characterize the pathogenesis of M. abscessus within this mouse model.  
SCID mice on a beige background are Rag2-/- mice on a beige background [49]. 
Again, we reiterate that the Rag2-/- indicates that these mice have no functional T cells 
or B cells [49]. The beige background renders the natural killer (NK) cells of these mice 
non-functional [49]. NK cells are cytotoxic cells which produce interferon-γ (IFN-γ) in 
response to infection [50]. IFN-γ protects against infection with Mycobacteria [51]. We 
will elaborate on this mechanism later in this discussion. NK cells also produce 
cytokines which enhance the T cell response to invading pathogens [50]. NK cells are 
known to protect against bacterial respiratory infections [50]. Dysfunction of 
microtubules in NK cells result from the beige mutation in beige mice [52]. This leads to 
the presence of giant granules in the cytoplasm of the NK cells, because they are 
unable to effectively degranulate [52]. Thus, the granzymes and perforins which would 
normally be released by NK cells in response to infection are not released [50, 52]. 
Hence, these NK cells are non-functional. In humans, such NK cell dysfunction resulting 
from analogous genetic mutation causes Chediak-Higashi syndrome [52]. Lysosomal 
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trafficking is disrupted in humans with Chediak-Higashi syndrome [53]. When this 
occurs in childhood, it is often lethal unless transplantation with hematopoietic stem 
cells can be performed before the disease begins to progress [53]. Symptoms include 
albinism, increased incidences of purulent bacterial infections, excessive bleeding, and 
neurological dysfunction [53].  
Minimum inhibitory concentrations (MIC) of standard and novel anti-mycobacterial 
compounds against M. abscessus can easily be determined in vitro using broth 
microdilution assays [54]. However, in vitro assays are poor models for infection and 
immune responses in humans. Furthermore, there is no definitive correlation between 
drug susceptibility of M. abscessus in vitro with drug efficacy in human patients [55]. 
Thus, it is important to develop a good in vivo model of pulmonary or disseminated M. 
abscessus infection in order to study pathogenesis and screen novel anti-mycobacterial 
compounds in an animal before going into clinical trials. Without such a model, the 
public would not be safe from potentially hazardous or lethal drug compounds. Previous 
studies have found that most mouse strains do not maintain a high level of infection 
over time, and do not become clinically ill. Thus, it is of the utmost importance to find 
and implement a mouse strain which remains ill with a high bacterial load in its organs 
into chronic infection in order to model the disease process in humans. The GM/Rag-
dblKO mice and the SCID mice on a beige background seem to fulfill this requirement, 
and hence, may be good models of M. abscessus infection and immune response in 
human patients. 
Previous studies established that most immunocompetent mouse strains exhibit 
clearance of M. abscessus in the first 8 weeks post-infection with the less virulent M. 
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abscessus isolates, making model development and selection difficult [6, 51]. These 
earlier studies infected C57BL/6 and leptin-deficient (Ob/Ob) mice with a low-dose 
aerosol (LDA, ~100 bacilli per mouse) which did not develop a progressive infection [6, 
51].  Conversely, when infected with a high-dose aerosol (HDA, ~1,000 bacilli per 
mouse), C57BL/6 and Ob/Ob mice developed an established infection and an early 
influx of IFN-γ+ cluster of differentiation 4 (CD4)+ T cells in the lungs [51]. This was a 
primary immune response which preempted the clearance of M. abscessus in both 
C57BL/6 and Ob/Ob mice [51].  On the other hand, IFN-γ knockout (GKO) mice infected 
with a LDA or HDA of M. abscessus yielded a progressive pulmonary infection related 
to the influx of T cells, macrophages, and dendritic cells leading to granuloma 
development [51]. Remarkably, a HDA M. abscessus infection of the GKO mice 
promoted the expansion of CD4+ and CD8+ T-cells able to produce IL-4 and IL-10 in 
the pulmonary cavity [51]. This was interesting because these are T helper 2 (TH2) 
polarizing cytokines, and are produced by TH2 cells [51]. One would expect to see a 
greater T helper 1 TH1 polarization in mice infected with an intracellular bacteria. 
However, the absence of IFN-γ likely allowed for the shift to the TH2 cytokines IL-4 and 
IL-10, which are immunosuppressive [51]. Thus, M. abscessus was capable of inflicting 
much more damage on the lungs of the GKO mice with HDA infection [51].  
Notwithstanding the aforesaid obstacles associated with establishing a 
progressive model of infection, further studies using mouse models with significant 
insufficiencies in innate or acquired immunity have given insight into immune clearance 
mechanisms and novel models of infection [6]. Initial studies established mice with 
specific deficits in innate or acquired immunity infected with 1x106 M. abscessus 
 
  10   
intravenously were able to control the infection [6]. Mouse strains capable of clearing M. 
abscessus include beige (dominant TH2 immunity), inducible nitric oxide synthase 
knockout (iNOS-/-), cytochrome b β (Cybb)-/- (devoid of super-oxide generating 
enzyme), TNFαR-/-, C3HeB/FeJ, GKO, and MyD88-/- mice [6]. Throughout a 40 day 
chronic infection, M. abscessus could still be detected at low levels in the lungs of the 
C3HeB/FeJ, GKO, and MyD88-/- mice [6]. Moreover, the GKO and MyD88-/- mice 
exhibited a decrease in the amount of M. abscessus in the spleen and liver after 40 
days [6]. 
Conversely, SCID, nude, and GM/Rag-dblKO mice infected intravenously with M. 
abscessus exhibited persistent or progressive M. abscessus burden, illustrating the 
critical importance of T and B cell immunity and GM-CSF reliant cell phenotypes for 
establishment of protective immunity against M. abscessus [6]. An advantage of using 
severely immunocompromised mice (SCID, nude, and GM/Rag-dblKO) for modelling M. 
abscessus infection was the occurrence of foamy cells, necrotizing, and non-necrotizing 
granulomas in the lungs 40 days post-infection, a cellular phenotype ordinarily observed 
in the histopathologic samples of human NTM lung disease [6].   
 
1.2 Classification of Nontuberculous Mycobacterial Strains 
 The development and acceptance of 16S rRNA gene sequencing has resulted in 
the identification of several new species of NTM [3, 4]. The mycobacterial 16S rRNA 
gene is highly conserved [4]. Thus, differences in the sequence of 1% or greater 
indicate a new species [4]. However, 16S rRNA gene sequencing is not a reliable 
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method for differentiating M. abscessus from M. chelonae because the two species only 
differ by 4 base pairs (bp) within the 16S rRNA genes [4].  
It is important to obtain species-level identification of NTM clinical isolates 
because differences in antimicrobial susceptibility determine treatment options [4]. 
Phenotypic testing of NTM species is comprised of two classification criteria, including 
growth rate and pigmentation [3, 4]. To identify NTM species by growth rate, the 
bacteria are classified as either rapidly growing mycobacteria (RGM), or slowly growing 
mycobacteria [4]. RGM are defined as clinical isolates of NTM which form colonies upon 
subculture in at most seven days [4]. Examples of RGM include M. abscessus, M. 
chelonae, and M. fortuitum. Slowly growing mycobacteria require more than 7 days to 
form isolated colonies upon subculture [4]. Examples of slowly growing mycobacteria 
include M. avium and M. intracellulare. Pigmentation is not used as frequently to identify 
Mycobacterial species, but it is clear that strains of M. tuberculosis lack pigmentation, 
and have rough colony morphology [4]. Thus, the presence of pigmentation or smooth 
colony morphology is indicative of a strain of NTM [4]. High performance liquid 
chromatography (HPLC) is a reliable method of species-level identification for slowly 
growing Mycobacteria, but not for RGM [4].  
The American Thoracic Society (ATS) and the Infectious Diseases Society of 
America (IDSA) recommend that Mycobacterium avium complex and Mycobacterium 
intracellulare do not need to be differentiated from each other because they are 
currently clinically identical, and treatment would not change based on species-level 
identification [4]. Additionally, ATS and IDSA suggest that PCR restriction endonuclease 
assay (PRA) be used to differentiate between M. abscessus, M. chelonae, and M. 
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fortuitum [4]. Also, the ATS and IDSA advise that susceptibility of RGM to amikacin, 
cefoxitin, clarithromycin, ciprofloxacin, doxycycline, linezolid, sulfamethoxazole, and 
tobramycin be used to obtain species-level identification of M. chelonae, M. abscessus, 
and M. fortuitum [4]. 
Aside from ATS recommendations, it has been suggested in more recent 
literature that rpoB gene sequencing will allow identification of M. abscessus even to the 
subspecies level [56]. In other words, sequencing the rpoB gene will allow one to 
determine whether the isolate in question is M. abscessus sbsp. abscessus, M. 
abscessus sbsp. massiliense, or M. abscessus sbsp. bolletii.   
 
1.3 Drug Resistance 
 As previously described, drug resistance is a major obstacle to treating M. 
abscessus infections. In this section, we will elaborate on the information provided in the 
Introduction regarding this drug resistance. All clinical isolates of M. abscessus are 
resistant to antituberculous drug therapies [4]. M. abscessus is multi-drug resistant [56]. 
Mutations in the 23S rRNA gene of M. abscessus can cause resistance to 
clarithromycin [4]. Additionally, mutations in the 16S rRNA gene of M. abscessus can 
lead to amikacin resistance [4]. M. abscessus tends to be susceptible in vitro to 
clarithromycin, amikacin, cefoxitin, imipenem, and clofazamine [4]. However, when 
treating pulmonary M. abscessus infections, there are no drug regimens that reliably 
result in sputum conversion from culture positive to culture negative over any 
considerable length of time [4]. Currently, the best course of action to treat pulmonary 
M. abscessus infections is to incorporate surgical resection of the affected lung tissue 
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as well as at least 12 months of rigorous combination antibiotic therapy using 
clarithromycin, amikacin, and cefoxitin [4]. In most cases, M. abscessus pulmonary 
infection is chronic and incurable [4]. 
 NTM create many obstacles to efficacious antibiotic therapy [3, 24, 25]. 
Mycobacteria have a hydrophobic cell envelope that provides significant protection 
against lipophilic antimycobacterials [8, 57, 58]. In addition, antibiotic inactivation plays 
a significant role in NTM drug resistance, with resistance mechanisms including β-
lactamases conferring resistance to β-lactams, which disrupt cell wall synthesis [28, 30, 
59]. Aminoglycoside phosphotransferases and aminoglycoside acetyltransferases, 
which have been produced by Mycobacteria are known to be responsible for bacterial 
resistance to aminoglycosides, such as amikacin [60]. Mycobacteria also display natural 
resistance to isoniazid, rifamycins, pyrazinamide ethambutol [61-63]. Rapidly growing 
mycobacteria are generally quite resistant to ethambutol [64].  As previously mentioned, 
the p55 efflux pump gives mycobacteria resistance to aminoglycosides as well as 
tetracyclines [3]. We reiterate here that any isolates of M. abscessus sbsp. abscessus, 
some isolates of M. abscessus sbsp. massiliense, and isolates of M. fortuitum have 
demonstrated expression of erythromycin ribosome methyltransferase (41) genes 
(erm(41) genes) [3, 24]. These erm(41) genes confer inducible macrolide resistance in 
these pathogens by methylation of the 23S rRNA [3, 24, 25]. These erm(41) genes are 
not found in M. chelonae [3]. The stimulation of erm(41), and subsequent macrolide 
resistance, is not detected by traditional susceptibility testing, because this requires 
prolonged incubation observation [65].  Azithromycin contributes less to inducible 
macrolide resistance than clarithromycin [66]. 
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Compounding the difficulty of drug development is the fact that in vitro 
susceptibility broth assays seldom correlate significantly with in vivo clinical efficacy [55, 
67]. Another obstacle to accurate in vitro testing of antimycobacterial compounds is that 
NTM form biofilm, which causes them to enter stationary phase, and leads to imprecise 
measurements of drug susceptibility [55].  
Moreover, there is sparse knowledge regarding pharmacokinetics of 
antimycobacterial compounds at the site of infection [67, 68]. There is a high degree of 
variability in the rates of loading of drug into the liposomes of macrophages from one 
compound to another, and so the pharmacokinetics and pharmacodynamics must be 
assessed for each individual compound tested, creating increased burden and expense 
for drug development [69]. As a result of these multiple resistance mechanisms paired 
with incorrect MIC and minimum bactericidal concentration (MBC) measurements, very 
few antibiotics have been identified through in vitro screening that have good in vivo 
activity against NTM [61-67]. The inadequacy of available chemotherapies against NTM 
poses serious challenges to effectively treating M. abscessus infections [70]. Often, 
surgical resection of infected lung tissue is required in order to eradicate the infection 




 The epidemiology, virulence and disease processes associated with NTM are 
poorly understood [71]. It has been challenging to demonstrate a causative relationship 
between NTM in the environment and transmission resulting in pulmonary infection, 
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disseminated disease and lymphadenitis [72]. Whole genome sequencing has shown 
evidence supporting person to person transmission of M. abscessus between patients 
with cystic fibrosis [16]. A continuing study by Dr. Jackson and Dr. Ordway on the 
virulence of M. abscessus sbsp massiliense has shown the extremely pathogenic 
nature of BRA100 outbreak isolates [73]. The BRA100 strain of M. abscessus is 
particularly virulent in part because of remodeling of the cell envelope leading to 
resistance to glutaraldehyde, a common disinfectant [73].  Nevertheless, this is only one 
study and future studies are mandatory to assess high and low transmission strains to 
shed light on the properties of virulence in our animal models. Given the chance, NTM 
result in worsening pulmonary infection, superficial lymphadenitis, disseminated 
disease, or skin and soft tissue infections [4].  
While HIV infected patients are more susceptible to infection with M. abscessus, 
usually disseminated infection will not begin until after CD4+ T cell numbers have been 
depleted beneath a certain threshold [4]. Thus, T cells provide some protective 
immunity against M. abscessus [4]. 
 Although cell-mediated, adaptive immunity is important and protective against M. 
abscessus infection, innate immunity is arguably more significant and crucial to fighting 
off infection with M. abscessus. NTM are phagocytosed by macrophages, which then 
produce interleukin-12 (IL-12) [4]. IL-12 production triggers expression of interferon-γ 
(IFN-γ) [74]. In turn, IFN-γ activates neutrophils and macrophages to kill mycobacteria 
and other intracellular pathogens [74]. IL-12 is produced principally by antigen 
presenting cells [74]. IL-12 receptors are found on T cells and NK cells [74]. IFN-γ is 
produced by T cells and NK cells [74]. Dysfunction in IFN-γ receptors 1 and 2 (IFNγR1 
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and IFNγR2) or in IL-12 receptor subunit IL-12Rβ1 and IL-12p40 have been shown to 
increase patient susceptibility to NTM infection because such mutations disrupt the 
polarization of TH1 cells [4, 74]. IL-12p40 is a bioactive form of IL-12, and functions as a 
chemoattractant which beckons macrophages and dendritic cells to the site of infection 
[75]. 
 Rough morphology of some M. abscessus strains contributes to hyper-virulence 
caused by cording, which allows for evasion of phagocytosis by macrophages [12]. 
Abscesses are formed by extensive cording of rough morphotypes of M. abscessus 
[12]. While moderate TNFα expression has been shown to be protective against 
mycobacterial infections, some studies show that rough variants of M. abscessus are 
easily recognized by Toll-like receptor 2 (TLR2) on macrophages because of their lack 
of GPL production [14]. This causes overexpression of TNFα, leading to pathologic 
inflammatory response [14]. These hyper-virulent rough variants of M. abscessus are 
subsequently more capable of invading lung tissue [14].  
 TLR2 signaling, mitogen-activated protein kinase (MAPK) signaling, and 
activation of the NF-κB pathway elicit TNF-α production by human monocytes in 
response to M. abscessus infection [14, 76]. Quickly following infection with M. 
abscessus, dendritic cells are activated by IL-12 p40 [14]. These activated dendritic 
cells then migrate to the mediastinal lymph nodes, where mycobacterial antigen is 
presented to naïve T cells [14]. This causes the differentiation and activation of effector 
T cells [14]. Further dissemination of M. abscessus is then prevented by the arrival of 
several monocytes, macrophages, neutrophils, and adaptive immune cells to the site of 
mycobacterial replication [14]. Thus, a granuloma is formed encapsulating the M. 
 
  17   
abscessus [14]. Finally, in immunocompetent hosts, CD4+ and CD8+ T cells secrete 
granulysin and perforin, which kill intracellular pathogens such as mycobacteria [14]. Of 
course, if an individual is infected with a variant of M. abscessus which is resistant to 
phagocytosis by macrophages, as is the case with rough variants of M. abscessus, then 
much of the necessary antigen presentation and cytotoxic killing of intracellular 




 The objective of this project is to identify small animal models which demonstrate 
a high bacterial burden in the lungs, spleens, and livers upon infection with M. 
abscessus, and which exhibit necrotic and non-necrotic granuloma formation in the 
lungs upon infection with M. abscessus. Additionally, we hope to find an animal model 
which has a similar immune response to that of the human upon infection with M. 
abscessus. Accordingly, our aims are as follows: 
 Aim 1: We will conduct a survival study and characterize the bacterial burden, 
organ pathology, and immune responses to M. abscessus in infected GM/Rag-dblKO 
and SCID mice on a beige background.  
Aim 2: We will characterize the bacterial burden, organ pathology, and immune 










2.1 Animal Infection 
 Mice were infected with a tail vein injection of 100 μL containing 1 × 106 colony 
forming units (CFU) of M. abscessus 103 with a rough colony morphology and positive 
for biofilm formation (a gift from Dr. Mary Jackson, Colorado State University). This 103 
strain is a clinical isolate of the subspecies bolletii. The M. abscessus inoculum was 
prepared by thawing the bacterial vial. Thereafter, the mycobacterial suspension was 
obtained from the vial with a 1-ml tuberculin syringe fitted with a 26.5-gauge needle and 
expelled back into the vial. This procedure was repeated back and forth into the vial 20 
times without removing the needle to mix the suspension and break up any small 
clumps of bacilli. All animals used were either SCID mice on a beige background 
(mouse strain: C.B-Igh-1b/GbmsTac-Prkdcscid-Lystbg N7) or GM/Rag-dblKO mice 
(mouse strain: C;129S4-Rag2tm1.1Flv Csf2/Il3tm1.1(CSF2,IL3)Flv Il2rgtm1.1Flv/J). 
 
2.2 Culturing of Nontuberculous Mycobacterial Strains 
 All strains of M. abscessus were grown in 7H9 broth with Glycerol, Dubos Oleic 
Albumin Complex (OADC), and Tween 80 to an optical density (OD) of 1.0, or a 
concentration of approximately 2.5 x 10^8 CFU / mL. The culture was then centrifuged 
at 3,500 revolutions per minute (rpm) for 10 minutes at 23°C. The bacterial cell pellet 
was resuspended in fresh 7H9 broth with glycerol, OADC, and Tween 80. This solution 
was again centrifuged for five minutes at 350 rpm at 23°C. The supernatant was saved, 
and the remaining pellet discarded. Finally, 1.5 mL of bacterial culture was pipetted into 
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glass vials, which were plugged and sealed. A titer was obtained for each final culture, 
and labelled vials were stored in cryovial boxes at -80°C. 
 
2.3 Clinical Strains 
 All strains of M. abscessus used in this study were clinical strains obtained from 
Dr. Steve Holland, National Institute of Allergy and Infectious Disease. The outbreak 
strains were obtained from Dr. Andres Floto (Cambridge, UK) (M. abscessus sbsp. 
massiliense OM194), Brazilian outbreak strain (M. abscessus sbsp. massiliense CRM-
0019) and the Seattle outbreak strain (M. abscessus sbsp. massiliense MC2638). 
 
2.4 Animal Model 
 The two mouse strains used in this study were GM/Rag-dblKO mice (mouse 
strain: C;129S4-Rag2tm1.1Flv Csf2/Il3tm1.1(CSF2,IL3)Flv Il2rgtm1.1Flv/J), and SCID 
mice on a beige background (mouse strain: CB17.Cg-PrkdcscidLystbg-j/Crl). The 
GM/Rag-dblKO mice were obtained from Jackson Laboratories, and have strain code 
014595. Six- to eight-week-old, specific-pathogen-free female SCID mice on a beige 
background were obtained from Charles River (Wilmington, MA), with stock number 
250. As stated in Chapter 1, the GM/Rag-dblKO mice have undergone a knock-out of 
the murine IL-3 and Csf2, and a subsequent knock-in of human IL-3 and human Csf2 
[41]. These GM/Rag-dblKO mice are on a Rag2, IL-2 knockout background [41]. The 





2.5 Bacterial Burden 
 On day one post-infection, three mice were euthanized and their lungs, spleens, 
and livers were harvested to determine the bacterial burden baseline. Organs were 
homogenized in phosphate-buffered saline (PBS), and serial dilutions were plated on 
nutrient 7H11 agar for 1 week at 30°C, when CFU were enumerated. 
 
2.6 Organ Histology 
 The whole lungs, livers, and spleens from M. abscessus 103 infected mice were 
fixed in 10% formalin, and left inside of a biosafety level 3 (BSL-3) barrier at CSU for 
two weeks at 4°C. The organs were then transported to a biosafety level 2 (BSL-2) 
laboratory at CSU, and the 10% formalin was discarded from the organs. Then the 
organs were placed in 70% ethanol at 4°C for at least two days.  
Next, the 70% ethanol was discarded from the organs, and the organs were 
immersed in 1XPBS at 4° C and sent to Premier Laboratories for histopathological 
analysis. 
 
2.7 Immune Responses 
 GM/Rag-dblKO mice were infected with 106 CFU of M. abscessus. On day 30 
and day 50, we humanely euthanized 5 infected mice from each group by carbon 






Immune Cell Isolation from Lungs and Spleens of Infected Mice 
Lungs, spleens, and small intestines of infected mice were placed in small petri 
dishes. A razor blade was dipped in 70% ethanol, and then dipped in incomplete 
Dulbecco’s Modified Eagle’s Medium (DMEM). Then the organs were chopped to 
disrupt the tissue in the petri dish using the razor blade, but still keeping the organs 
intact. Next each organ was returned to a 15 mL conical vial. At that point 1 mL of a 
collagenase / DNase mixture in DMEM was added to each conical vial containing an 
organ. The collagenase / DNase mixture was prepared by preparing a 1:5 dilution of our 
collagenase / DNase diluted with DMEM. After adding the collagenase / DNase to each 
conical vial containing an organ, the vials were incubated in a rocking water bath at 
37°C for 30 minutes. Following this incubation, the conical tubes were placed on ice to 
neutralize the collagenase / DNase.  
Next, sterile cell strainers were placed in small petri dishes. The contents of the 
15 mL conical vials containing the organs were emptied into the cell strainers, and 
sterile plungers from a 5 mL syringe were used to push the organs through the cell 
strainers. We then pipetted 6 mL of incomplete DMEM into the cell strainer to rinse the 
cells into the petri dish. Next, the contents of each petri dish were pipetted back into 
each 15 mL conical vial. These vials were then centrifuged at 1300 rpm for 10 minutes 
at 4°C. Then the supernatant was discarded, and the cell pellet in each vial was 
disrupted by scraping the vial along the inside surface of the biosafety cabinet.  
In order to lyse the red blood cells isolated from each organ, 1 mL of Gey’s 
solution was added to each vial. The organs were incubated in the Gey’s solution for 
five minutes at room temperature. After incubation, 5 mL of complete DMEM were 
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added to each conical vial in order to neutralize the Gey’s solution. Again, the tubes 
were centrifuged at 1300 rpm for 10 minutes at 4°C. Then the supernatant was 
discarded, and the cell pellet was resuspended in complete DMEM. The organs were 
then incubated in the 37°C CO2 incubator for three hours.  
 
Cell Staining 
  We stained the isolated cells from the lungs, spleens, and small intestines of M. 
abscessus infected mice for markers of M cells, dendritic cells, macrophages, and 
neutrophils, including CD11b, CD11c, IL-4, IL-12, major histocompatibility complex 
class II (MHC II), IL-10, and Gr-1. We also stained for diverse T-cell populations 
including CD4+, CD8+, IL-4+, Programmed cell death protein 1 (PD1)+, forkhead box 
P3 (FoxP3)+, IL-17+, and IFN-γ+ T-cells (Table 1). Fluorophores used for staining were 
fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein 
complex (PerCP), Allophycocyanin (APC), efluor 450 (ef450), Alexa fluor 700 (A700), 
and phycoerythrin-cyanine7 (Pe-Cy7) (Table 1). We repeated this process again on Day 
51. We used Fluorescence Minus One controls for compensation. We analyzed our 
data in Excel by comparing the percentage of the diverse cell populations to the 
percentage of the parent cell population. 
 
2.8 Survival Study 
 Six SCID mice on a beige background and five GM/Rag-dblKO mice were 
infected with 106 CFU of M. abscessus 103 by intravenous tail injection. A group size of 
n=5 was sufficient given the power analysis which we share in section 2.9. These mice 
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remained untreated throughout the duration of the study. We, and staff at Colorado 
State University’s Lab Animal Resources (LAR), monitored the mice daily for signs of 
distress indicating sickness from infection. If mice became distressed, they were 
humanely euthanized by CO2 inhalation, and their whole lungs, livers, and spleens were 
harvested. Every other mouse which succumbed to disease was selected to have their 
organs sent out for histology, and the other mouse organs were used to assess 
bacterial burden in the organs. 
 A Kaplan-Meier survival plot of the survival rates over time post-infection of the 
SCID mice on a beige background and GM/Rag-dblKO mice was graphed using 
GraphPad Prism. 
 
2.9 Statistical Analysis 
Bacterial burdens in the M. abscessus infected animal organs were analyzed 
with GraphPad Prism version 4 (GraphPad Software, San Diego, CA), using analysis of 
variance (ANOVA) and Dunnett and Tukey multiple comparison tests. Data are 
presented using the mean values (n = 5) plus or minus the standard error of the mean 
(SEM). Significance was considered below a P value of p<0.050. 
A Kaplan-Meier analysis was carried out on the survival data obtained from M. 
abscessus infected SCID mice on a beige background and GM/Rag-dblKO mice in the 










3.1 Development of Mouse Models 
 Several mouse strains have been screened for susceptibility to infection with M. 
abscessus [6]. Recent research has found that many mouse strains clear bacterial 
infection quickly, and do not achieve acute infection (Table 2) [6]. However, in previous 
studies, it was discovered that among mice with immune defects, Nude mice, SCID 
mice, and GM/Rag-dblKO mice demonstrate a high level of infection (Figure 1) [6]. Of 
these three immune defective mouse strains, SCID mice and GM/Rag-dblKO mice 
exhibited the highest levels of infection upon intravenous inoculation with M. abscessus 
103 [6]. Additionally, SCID mice were the only mouse strain of these three immune 
defective mice which produced both necrotic and non-necrotic granulomas in the lungs 
[6] (Figure 2). The GM/Rag-dblKO mice and Nude mice only exhibited non-necrotic 
granulomas in the lungs [6]. Thus, a survival study was carried out to determine the 
effects of chronic M. abscessus infection in SCID mice on a beige background and 
GM/Rag-dblKO mice (Figure 3). 
Upon infection with M. abscessus 103, GM/Rag-dblKO mice demonstrate much 
lower survival rates than those of SCID mice on a beige background. In fact, some 







3.2 Pathogenesis of M. abscessus 
 M. abscessus infected GM/Rag-dblKO mice exhibited severe lung consolidation 
upon examination of lung histology due to coalescence of granulomas in the lungs 
(Figure 4). While AFB were detected in the pulmonary tissue of both GM/Rag-dblKO 
mice and SCID mice on a beige background, bacillary load was much more extensive in 
the GM/Rag-dblKO mice than in the SCID mice on a beige background (Figure 5). 
 Alveolar macrophages are observed in the lung histology of both the GM/Rag-
dblKO and SCID mice on a beige background, but the excess of AFB seen in the lung 
histology of GM/Rag-dblKO mice compared to SCID mice on a beige background 
revealed that only the macrophages in the SCID on a beige background mouse lungs 
are effectively clearing AFB from the tissue. It is apparent from acid fast staining that 
many more AFB are surviving within the alveolar macrophages of the GM/Rag-dblKO 

















4.1 Global Circulating Clones 
 For decades, it has been generally accepted that NTM infection was acquired 
through environmental contamination, by contact with NTM strains in tap water and soil 
[2, 77-79]. In a global collaboration, we found strong evidence of indirect human to 
human transmission of M. abscessus [80]. While previous studies have shown that 
individual patients are infected with genetically disparate strains of M. abscessus, this 
study has shown via whole genome sequencing that individual cystic fibrosis patients 
have been infected with genetically identical, globally circulating strains of M. abscessus 
[80-83]. Patients in a cystic fibrosis center in the UK were grouped into two clusters [80]. 
Each cluster consisted of patients with genetically indistinguishable isolates of M. 
abscessus [80]. Moreover, patients at a cystic fibrosis treatment facility in Seattle, 
Washington were found to have the same isolates of M. abscessus as those in the UK 
treatment facility [80]. We determined that these M. abscessus strains were transmitted 
via indirect human-to-human transmission within the treatment facilities, using social 
network analysis [80]. Further similar analysis was conducted using 1,080 M. abscessus 
isolates from 517 infected individuals being treated at various cystic fibrosis clinics in 
the UK, the United States of America, Ireland, Denmark, Sweden, the Netherlands, and 
Australia  [80]. The majority, 730 of the NTM strains isolated, were identified as M. 
abscessus sbsp. abscessus [80]. Next, there were 256 of the 1,080 M. abscessus 
isolates which were identified as M. abscessus massiliense [80]. Finally, the least 
prevalent of the isolates was M. abscessus bolletii, with only 91 of the isolates being so 
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identified [80]. Phylogenetic analysis revealed that while environmental acquisition of 
unclustered M. abscessus was still occurring, there were also groups of nearly 
genetically identical, clustered isolates of M. abscessus from different regions [80]. It 
was concluded that human-transmissible, globally circulating clones of M. abscessus 
are emerging among cystic fibrosis patients and becoming clinically significant [80].  
 In a separate study, Tettelin, et al. used whole genome sequencing to identify 
nearly identical outbreak strains in cystic fibrosis patients in the UK, the United States, 
and Brazil [84]. Our collaborators shared these outbreak strain isolates with us, and we 
infected GM/Rag-dblKO mice with them. Then we performed flow cytometry, counted 
viable CFU, and carried out histological analyses of the lungs of these infected 
GM/Rag-dblKO mice. The strains used were M. massiliense outbreak strain CRM-0019 
(Brazil), M. massiliense outbreak strain MC2638 (Seattle, USA), and M. massiliense 
outbreak strain OM194 (Cambridge, UK) [84]. 
 
4.2 M. abscessus Virulence 
 In order to determine whether there are disparities in the virulence of clustered 
versus unclustered isolates of M. abscessus, we carried out various phenotypic 
classifications of the clinically isolated clustered and unclustered strains [80]. No 
differences were detected between clustered and unclustered strains regarding colony 
morphology, biofilm formation, or capability to induce the expression of cytokines by 
macrophages [80]. However, there were significant differences in the rate of 
phagocytosis of clustered versus unclustered M. abscessus isolates by macrophages 
and the ability of clustered versus unclustered M. abscessus isolates to survive within 
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macrophages (Figure 6) [80]. Additionally, there were significant increases in the 
number of viable colony forming units of clustered M. abscessus strains when 
compared with unclustered M. abscessus strains in the lungs of SCID mice (Figure 6) 
[80]. 
The outbreak strains first classified by Tettelin, et al. were used to infect 
GM/Rag-dblKO mice. The viable colony forming units in their lungs, spleens, and livers 
were counted (Figure 7). The lungs, spleens, and livers of the GM/Rag-dblKO mice 
maintained a high bacterial burden when infected with these outbreak strains. Thus, the 
strains were found to be quite virulent in GM/Rag-dblKO mice. 
 
4.3 Immune Responses to M. abscessus 
 In this study, we established that there was significantly increased phagocytosis 
of clustered M. abscessus strains by macrophages than that of unclustered M. 
abscessus strains [80]. Also, clustered strains of M. abscessus demonstrated greater 
intracellular survival than unclustered strains of M. abscessus (Figure 8) [80]. However, 
the cytokine profiles of macrophages responding to clustered versus unclustered M. 
abscessus strains were not significantly different [80]. Additionally, there was no 
significant difference in the biofilm formation observed in clustered M. abscessus strains 
when compared with unclustered M. abscessus strains [80].  
 Flow cytometry was performed on cells isolated from the lungs of GM/Rag-dblKO 
mice infected with the outbreak strains first described by Tettelin, et al [84]. It was 
observed that there were more polymorphonuclear cells (stained for Gr-1 with PeCy7), 
macrophages (stained for CD11c and MHC II using PE and ef450, respectively), and 
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dendritic cells (stained for CD11b and MHC II using FITC and ef450, respectively) in the 
lungs of GM/Rag-dblKO mice infected with M. abscessus sbsp. massiliense strains 
OM194 (Cambridge) and CRM-0019 (Brazil) (Figure 9). However, the outbreak strain M. 
abscessus sbsp. massiliense MC2638 (Seattle) infected GM/Rag-dblKO mouse lungs 
had fewer polymorphonuclear cells in their lungs, an increase in macrophages in the 
lungs, and only a slight increase in dendritic cells in the lungs between day 30 and day 
50 post-infection (Figure 9). 
 Furthermore, double staining with PE and ef450 revealed that major 
histocompatibility complex class II (MHC II) was upregulated on macrophages from day 
30 to day 50 post-infection of GM/Rag-dblKO mice infected with the outbreak strains M. 
abscessus sbsp. massiliense OM194 and MC2638 (Figure 10). Conversely, MHC II was 
down-regulated on macrophages in the lungs of GM/Rag-dblKO mice infected with the 
outbreak strain M. abscessus sbsp. massiliense CRM-0019 from day 30 to day 50 post-
infection. No significant change was observed in the level of expression of MHC II on 
dendritic cells in the lungs of GM/Rag-dblKO mice infected with the outbreak strains M. 
abscessus sbsp. massiliense OM194 and CRM-0019. There was mild down-regulation 
of MHC II on dendritic cells in the lungs of GM/Rag-dblKO mice infected with the 
outbreak strain M. abscessus sbsp. massiliense MC2638. 
Moreover, we observed decreased IL-12 production (by staining with APC for  
IL-12) by macrophages and dendritic cells in the lungs of GM/Rag-dblKO mice infected 
with outbreak strains M. abscessus sbsp. massiliense OM194 and CRM-0019, when 
compared with those mice infected with the outbreak strain M. abscessus sbsp. 
massiliense MC2638 (Figure 11).  
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 Finally, there was much more production of IL-10 by macrophages and dendritic 
cells in the lungs of GM/Rag-dblKO mice infected with the outbreak strains OM194 and 
CRM-0019 than in the lungs of GM/Rag-dblKO mice infected with the outbreak strain 
MC2638 (Figure 12). 
 
4.4 Pathogenesis of Major Clones 
 There was a significant increase in granulomatous inflammation in the lungs of 
SCID mice in response to infection with clustered M. abscessus strains versus 
unclustered M. abscessus strains (Figure 13) [80]. 
 In this study, Bryant, et. al have established that the clustered globally circulating 
clones of M. abscessus are being transmitted by fomites [80]. Individual cystic fibrosis 
patients may be contaminating the surfaces in the rooms of their treatment centers [80]. 
In addition, it is surmised that M. abscessus may be spread by aerosols which linger for 
quite some time, and which are generated when infected patients cough [80]. Clustered 
strains of M. abscessus obtained mutations in their 16S ribosomal RNA which provided  
resistance to amikacin, contributing to increases in chronic infection in affected cystic 
fibrosis patients [80]. Similarly, clustered M. abscessus clones acquired mutations in 
their 23S ribosomal RNA which conferred resistance to macrolides, making chronic 
infection incredibly difficult to treat [80]. 
 In a separate study, histological analysis was performed on the lungs of GM/Rag-
dblKO mice infected with one of the outbreak strains M. abscessus sbsp. massiliense 








We carried out a survival study in GM/Rag-dblKO mice and SCID mice on a 
beige background infected with M. abscessus 103, in order to see how these mice 
responded during chronic infection. We observed a much shorter survival time in 
GM/Rag-dblKO mice compared with SCID mice on a beige background. Since GM/Rag-
dblKO mice have no functional neutrophils, macrophages, or lymphocytes, they are 
even less capable of mounting an effective immune response against M. abscessus 
than the lymphocyte-depleted SCID mice on a beige background. We will be more likely 
to see a significant difference in GM/Rag-dblKO mice in the survival times of drug-
treated, infected mice compared with those of untreated, infected mice. 
In our survival study, we prepared the lungs of the M. abscessus 103 infected 
GM/Rag-dblKO mice and SCID mice on a beige background for histological analysis. 
H&E staining of the lungs of M. abscessus infected GM/Rag-dblKO mice exhibited 
severe lung consolidation upon examination of lung histology due to coalescence of 
granulomas in the lungs. While acid fast staining revealed that AFB were detected in the 
pulmonary tissue of both GM/Rag-dblKO mice and SCID mice on a beige background, 
bacillary load was much more extensive in the GM/Rag-dblKO mice than in the SCID 
mice on a beige background. 
 Alveolar macrophages are detected in the lung histology of both the GM/Rag-
dblKO and SCID mice on a beige background, but the plethora of AFB observed in the 
lungs of GM/Rag-dblKO mice compared to SCID mice on a beige background revealed 
that only the macrophages in the SCID on a beige background mouse lungs are 
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effectually clearing AFB from the tissue. It is clear from acid fast staining that additional 
AFB are persisting in the alveolar macrophages of the GM/Rag-dblKO mice than in 
those of the SCID mice on a beige background. 
To discover whether or not there are differences in the virulence of clustered 
versus unclustered isolates of M. abscessus, we performed many phenotypic 
classifications of the clinically isolated clustered and unclustered strains [80]. There 
were significant differences in the rate of phagocytosis of clustered versus unclustered 
M. abscessus strains by macrophages and the capability of clustered versus 
unclustered M. abscessus strains to survive within macrophages [80]. In addition, there 
were significant increases in the quantity of viable colony forming units of clustered M. 
abscessus isolates when compared with unclustered M. abscessus isolates in the lungs 
of SCID mice [80]. Thus, the emergence of global circulating clones of M. abscessus 
may be due to increased transmissibility and worsening virulence [80]. Because there 
was no evidence of contact between cystic fibrosis patients in disparate geographical 
regions across the globe, it can be assumed that zoonotic transmission and 
environmental vectors are responsible for the spread of nearly identical strains of M. 
abscessus [80]. Since clustered isolates of M. abscessus are more virulent than 
unclustered strains, it is clear that global circulating clones have altered phenotypes that 
are allowing increased transmission and worsening infections [80].  
 The outbreak strains first classified by Tettelin, et al. were used to infect 
GM/Rag-dblKO mice. The viable colony forming units in lungs, spleens, and livers of 
infected GM/Rag-dblKO mice were quantified. We observed increased bacillary load in 
the lungs, spleens, and livers of GM/Rag-dblKO mice infected with the outbreak strains 
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M. abscessus sbsp. massiliense OM194, CRM-0019, and MC2638. Additionally, 
histological analysis revealed that there was worse lung pathology observed in 
GM/Rag-dblKO mice infected with these outbreak strains. The increased virulence 
demonstrated by these outbreak strains may account for their persistence and person-
to-person transmission in cystic fibrosis patients.  
 We reiterate here that GM/Rag-dblKO mice develop non-functional 
polymorphonuclear cells and alveolar macrophages [42]. While flow cytometry of cells 
isolated from GM/Rag-dblKO mice infected with the outbreak strains M. abscessus 
sbsp. massiliense OM194, CRM-0019, and MC2638 revealed that there were increased 
numbers of granulocytes and macrophages produced by these infected mice, they were 
not functional granulocytes or macrophages, which accounts for the decreased 
production of IL-12 and MHC II by macrophages and dendritic cells. Furthermore, it 
seems that these outbreak strains are managing to survive intracellularly, and this may 
be due in part to the stimulation of IL-10 production, since IL-10 decreases the 
inflammatory response. On the other hand, this cytokine milieu may only be a result of 
the use of the GM/Rag-dblKO mouse which has no functional macrophages or 
granulocytes, and which has no functional T cells. Yet, the GM/Rag-dblKO mouse is a 
good model of cystic fibrosis, and so we can see a snapshot of what may be occurring 
in these susceptible patients. 
When screening candidate mouse strains to model human NTM infection, 
Obregón-Henao, et al. found that SCID, GM/Rag-dblKO, and Nude mice achieved a 
high level of infection [6]. This high bacterial burden in SCID mice is not surprising. 
Since the SCID mice have a Rag2 knockout, they have no T cells or B cells. Thus, they 
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cannot mount a TH1 response to promote the production of IFN-γ. Hence, SCID mice 
are unable to clear the mycobacterial infection. This implies that SCID mice model 
human NTM infection, and are a useful candidate for novel antimycobacterial drug 
screening because a high level of infection ensures that if drug treatments are effective, 
then there will be a significant difference in the number of M. abscessus CFU found in 
the organs of drug-treated, infected mice compared with untreated, infected mice. 
 The lack of lymphocytes, neutrophils, and macrophages in the GM/Rag-dblKO 
mice explains the high bacterial load maintained in the organs of these mice. These 
mice are unable to mount any adaptive or innate immune response to infection. 
Therefore, the GM/Rag-dblKO mouse model is an appropriate candidate for screening 
novel antimycobacterial drugs. The SCID mice were the only mice in which both 
necrotizing and non-necrotizing granulomas were observed [6]. Since humans develop 
both necrotizing and non-necrotizing granulomas, the SCID mouse model is a useful 














Table 1. Mouse Strains. This is a guide to the specific mutations of the mouse strains 
used in this study. 
Mouse Strain KO’s KI’s Background 




IL-2 KO, Rag2 KO 




Table 2. Screening of Animal Models. Animal models were screened for susceptibility 
to M. abscessus infection [6]. Animal models which maintained a high level of infection 
are in blue, animal models which cleared the bacteria are in red, and those animal 






Figure 1. Bacterial Burden in Lungs, Spleens, and Livers of Nude, SCID, and 
GM/Rag-dblKO Mice. A high mean bacterial load is maintained in Nude, SCID, and 
GM/Rag-dblKO mice upon intravenous infection with M. abscessus 103 [6]. Please note 
that this figure was originally published by Obregón-Henao, et al. and has been slightly 




Figure 2. Lung Histopathology of M. abscessus Infected SCID, GM/Rag-dblKO, and Nude Mice. Necrotic and non-
necrotic granulomas formed in SCID mice, while only non-necrotic granulomas formed in GM/Rag-dblKO and Nude mice 
upon infection with M. abscessus 103 [6]. Please note that this figure was originally published by Obregón-Henao, et al. 





Figure 3. Kaplan-Meier survival plot of SCID mice on a beige background and 
GM/Rag-dblKO mice post-infection with M. abscessus 103. There were 6 SCID 













Survival after Infection with M. abscessus 103































Figure 4. Lung Histopathology of M. abscessus infected GM/Rag-dblKO Mice and SCID mice on a beige 
background. Lung histopathology of M. abscessus infected GM/Rag-dblKO (n=3) and SCID mice on a beige background 
(n=3) from our survival study revealed quicker development of more extensive lung consolidation in GM/Rag-dblKO mice 





Figure 5. Acid Fast Staining of M. abscessus 103 Infected SCID Mice on a Beige Background and GM/Rag-dblKO 
Mice. Acid fast staining revealed that GM/Rag-dblKO mice (n=3) develop higher bacillary load much more rapidly than 
SCID mice on a beige background (n=3), as seen in histological analysis of pulmonary tissue taken from M. abscessus 






Figure 6. Phenotypic Characterization of Clustered versus Unclustered Strains of 
M. abscessus. Infection of SCID mice with clustered M. a. abscessus (blue) and M. a. 
massiliense (red) resulted in increased intracellular survival within bone marrow–derived 
macrophages, and higher bacterial loads in the lung after inoculation with 1 × 107 bacilli 
per animal [80]. Colony-forming units data are shown as mean ± SEM; *P < 0.05; **P < 







Figure 7. Increased bacteria in the lungs, spleens and livers of GM/Rag-dblKO 
mice infected with M. massiliense outbreak strain OM194.  Bacterial counts in the 
lungs (A) and spleens (B), and livers (C) on days 1, 30 and 50 from GM/Rag-dblKO 
mice infected with an intravenous infection of 106 CFU mouse the M. 
massiliense outbreak strain CRM-0019 (Brazil), M. massiliense outbreak strain MC2638 
(Seattle, USA) and M. massiliense  outbreak strain OM194 (Cambridge , UK) were 
compared. Results are expressed as the mean (n=5) of the bacterial load in each group 












Figure 8. Intracellular Survival of Clustered versus Unclustered Isolates of M. 
abscessus. In vitro phenotyping of representative isolates of clustered (blue) and 
unclustered (green) M. a. abscessus and clustered (red) and unclustered (yellow) M. a. 
massiliense comparing intracellular survival within differentiated THP1 cells. Data points 
represent averages of at least three independent replicates. *P < 0.05; **P < 0.005 (two-
















Figure 9. Immune Response of GM/Rag-dblKO Mice upon Infection with Outbreak 
Strains of M. abscessus. A) Increases were observed in the number of 
polymorphonuclear cells in the lungs of M. abscessus sbsp. massiliense outbreak strain 
OM194 (Cambridge) and CRM-0019 (Brazil) infected GM/Rag-dblKO mice. A decrease 
in the number of polymorphonuclear cells was observed in the lungs of GM/Rag-dblKO 
mice infected with M. abscessus sbsp. massiliense strain MC2638 (Seattle). B and C) 
Increases were observed in the number of macrophages and dendritic cells in the lungs 
of GM/Rag-dblKO mice infected with each of the M. abscessus sbsp. massiliense 








Figure 10. MHC Class II Expression in Antigen Presenting Cells of GM/Rag-dblKO 
Mice upon Infection with M. abscessus Outbreak Strains. A) MHC II was 
upregulated on macrophages in the lungs of GM/Rag-dblKO mice infected with the 
outbreak strains M. abscessus sbsp. massiliense OM194 and MC2638 between day 30 
and day 50 post-infection. There was a significant decrease in the level of expression 
from day 30 to day 50 post-infection of MHC II on macrophages in the lungs of GM/Rag-
dblKO mice infected with M. abscessus sbsp. massiliense CRM-0019. B) No change 
was observed in the level of expression of MHC II on the dendritic cells in the lungs of 
GM/Rag-dblKO mice infected with outbreak strain M. abscessus sbsp. massiliense 
OM194 or CRM-0019. There was a slight decrease in the level of expression of MHC II 
on dendritic cells in the lungs of GM/Rag-dblKO mice infected with the outbreak strain 









Figure 11. IL-12 Expression by Antigen Presenting Cells in the Lungs of GM/Rag-
dblKO Mice upon Infection with M. abscessus Outbreak Strains. There was less 
expression of IL-12 by macrophages (A) and dendritic cells (B) in the lungs of GM/Rag-
dblKO mice infected with outbreak strains M. abscessus sbsp. massiliense OM194 
(Cambridge) and CRM-0019 (Brazil) when compared with GM/Rag-dblKO mice infected 













Figure 12. IL-10 Expression by Antigen Presenting Cells in the Lungs of GM/Rag-
dblKO Mice upon Infection with M. abscessus Outbreak Strains.  The level of 
expression of IL-10 by the macrophages (A) and dendritic cells (B) was much higher in 
the lungs of GM/Rag-dblKO mice infected with the outbreak strains M. abscessus sbsp. 
massiliense OM194 and CRM-0019 compared with GM/Rag-dblKO mice infected with 












Figure 13. Lung Histopathology of SCID Mice Following Infection with Clustered versus Unclustered M. 
abscessus Isolates. Infection of SCID mice with clustered M. a. abscessus (blue) and M. a. massiliense (red) resulted in 





Figure 14. Granulomatous Inflammation in the Lungs of GM/Rag-dblKO Mice Infected with Outbreak Strains of M. 
abscessus. Granulomatous inflammation is seen in the lungs of GM/Rag-dblKO mice infected with the outbreak strains 
M. abscessus sbsp. massiliense OM194 (Cambridge), CRM-0019 (Brazil), and MC2638 (Seattle). The granulomas have 
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A700           Alexa fluor 700 
AFB           Acid Fast Bacillus 
ANOVA        Analysis of variance 
APC           Allophycocyanin 
APC           Antigen Presenting Cells 
ATS           American Thoracic Society 
bp           base pairs 
BSL-2           biosafety level 2 
BSL-3           biosafety level 3 
C57bl/6        C57 black 6 
CD11b          Cluster of differentiation 11b 
CD11c          Cluster of differentiation 11c  
CD4           Cluster of differentiation 4 
CD8           Cluster of differentiation 8 
CFU           Colony forming units 
CO2           Carbon dioxide 
Csf2           Colony stimulating factor 2 
Cybb           Cytochrome b β 
DMEM          Dulbecco’s Modified Eagle’s Medium 
ef450           efluor 450 




FITC           Fluorescein isothiocyanate 
FoxP3          Forkhead box P3 
GKO           IFN-γ knockout 
GPL           Glycopeptidolipid 
HDA           High-dose aerosol 
HPLC           High performance liquid chromatography 
IDSA           Infectious Diseases Society of America 
IFN-γ           Interferon-γ 
IFNγR1        Interferon-γ receptor 1 
IFNγR2        Interferon-γ receptor 2 
IL-2           Interleukin-2 
IL-3           Interleukin-3 
IL-4           Interleukin-4 
IL-10           Interleukin-10 
IL-12           Interleukin-12 
IL-12p40      Interleukin-12 p40 
IL-12Rβ1     Interleukin-12 receptor subunit β1 
IL-17           Interleukin-17 
IL-32           Interleukin-32 
iNOS           Inducible nitric oxide synthase 
LAR           Lab Animal Resources 
LDA           Low-dose aerosol 




MBC           Minimum bactericidal concentration 
MFI           Mean Fluorescence Intensity 
MHC II          Major histocompatibility complex class II 
MIC           Minimum inhibitory concentration 
MyD88         Myeloid differentiation primary response gene 88 
NF-κB          Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK           Natural Killer 
NTM           Non-tuberculous Mycobacteria 
OADC         Dubos Oleic Albumin Complex 
Ob/Ob         Leptin-deficient mice 
OD          Optical Density 
PBS          Phosphate Buffered Saline 
PD1          Programmed Cell Death Protein 1 
PE          Phycoerythrin 
PE-Cy7       Phycoerythrin-Cyanine7 
PerCP         Peridinin chlorophyll protein complex  
PRA          PCR restriction endonuclease assay 
Rag2-/-        Recombinant Activating Factor 2 knockout 
RGM           Rapidly Growing Mycobacteria 
rpm           Revolutions per minute 
rRNA           Ribosomal RNA 
SCID           Severe Combined Immunodeficiency 




TH1           T helper 1 
TH2           T helper 2 
TLR2           Toll-Like Receptor 2 
TLRs           Toll-Like Receptors 
TNFα           Tumor Necrosis Factor α 
TNFαR         Tumor Necrosis Factor α Receptor 
 
